Home » Advocacy » Letters, Testimony & Comments

Letters, Testimony & Comments

International Clinical Trials Registry Platform
September 30, 2005
Revisions to Payment Policies Under the Physician Fee Schedule
September 30, 2005
Comments by BIO; CMS-1502-P (Medicare Program; Revisions to Payment Policies Under the Physician Fee Schedule for Calendar Year 2006)
Proposed Changes to OPPS
September 16, 2005
Comments by BIO; CMS-1501-P (Medicare Program; Proposed Changes to Hospital Outpatient Prospective Payment System and Calendar Year 2006 Payment Rates) - NonPass-Throughs; Orphan Drugs; Vaccines; and Drug Administration
BIO Testimony on Patent Reform
September 16, 2005
BIO Response to PTO's Green Paper
September 14, 2005
Jim Greenwood Keynote Address at BioJapan 2005
September 7, 2005
I am honored to be part of this celebration of biotechnology in Japan. The turnout and excitement here today speak to the progress the Japanese biotech industry is making on every front: in the research laboratories, in the media, in the halls of...
CMS's Competitive Acquisition Program
September 6, 2005
Comments by BIO; CMS-1325-IFC (Medicare Program; Competative Acquisition of Outpatient Drugs and Biologicals Under Part B)
FDA's "Drug Watch" for Emerging Drug Safety Information
August 8, 2005
Comments by BIO; FDA Draft guidance; Docket 0062, Federal Register: May 10, 2005 (Volume 70, No. 89)
SBIR: Letter from Biotech CEOs
July 26, 2005
The letter, signed by over 280 biotech executives, emphasizes support for restoring eligibility in the SBIR program to venture-backed bioscience companies.
Exploratory Investigational New Drug (IND) Studies
July 13, 2005
Comments by BIO; FDA Docket 2005D-0122
Purdue Pharma V. Endo Pharmaceuticals
June 28, 2005
Comments on the draft Guideline on Similar Biological Medicinal Products Containing Biotechnology-Derived Proteins as Active Substance
June 17, 2005
Jim Greenwood Gives the Keynote Address to Annual Meeting of the Massachusetts Biotechnology Council
June 15, 2005
Thanks to Speaker Tom Finneran and to Massachusetts Biotechnology Council for the opportunity to be with you today. Mr. Speaker, I seek unanimous consent to address the house. I'm from Bucks County, Pennsylvania - just outside of...
BIO comments regarding coverage with evidence development
June 6, 2005
BIO letter on Patent Reform
May 13, 2005
BIO letter to Governor Murkowski expressing concern with Senate Bill 25
May 11, 2005
Dear Governor Murkowski: On behalf of the Biotechnology Industry Organization (BIO), we would like to express concern about a bill before you: Senate Bill 25, “An Act relating to labeling and identification of genetically modified fish...
BIO testimony opposing CA Assembly Bill 984 regarding manufacturer liability for agricultural biotechnology products.
April 29, 2005
Testimony of the Biotechnology Industry Organization Submitted to the California Assembly Committee on Agriculture April 29, 2005 Regarding Assembly Bill 984: Manufacturer Liability On behalf of the members of the Biotechnology Industry...
BIO testimony opposing CA Assembly Bill 984 regarding manufacturer liability for agricultural biotechnology products.
April 29, 2005
Testimony to the California Assembly Committee on Agriculture regarding Assembly Bill 984: Manufacturer Liability
Comments on Draft Guidance on Nonclinical Safety Evaluation of Drug Combinations
April 26, 2005
Docket No. 2005D-0004, Federal Register: January 26th, 2005 (Volume 70, Pages 3714-3715).
Testimony before the Texas House
April 11, 2005
Testimony of the Biotechnology Industry Organization (BIO) Before the Texas House of Representatives State Affairs Committee Regarding House Bill 1929 The Use of Human Cells and Tissue Thank you for the opportunity to present testimony today in...